154 related articles for article (PubMed ID: 25427105)
1. Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry.
Kim YG; Suh JW; Park JJ; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
PLoS One; 2014; 9(11):e114053. PubMed ID: 25427105
[TBL] [Abstract][Full Text] [Related]
2. Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?
Pendyala LK; Loh JP; Lhermusier T; Minha S; Magalhaes MA; Torguson R; Chen F; Satler LF; Pichard AD; Waksman R
Am Heart J; 2014 Oct; 168(4):545-51. PubMed ID: 25262265
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
Gremmel T; Koppensteiner R; Panzer S
PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention.
Ko YG; Suh JW; Kim BH; Lee CJ; Kim JS; Choi D; Hong MK; Seo MK; Youn TJ; Chae IH; Choi DJ; Jang Y
Am Heart J; 2011 Feb; 161(2):383-90. PubMed ID: 21315223
[TBL] [Abstract][Full Text] [Related]
6. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
[TBL] [Abstract][Full Text] [Related]
7. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
8. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
9. Comparison of factors affecting platelet reactivity in various platelet function tests.
Choi SY; Kim MH
Platelets; 2019; 30(5):631-636. PubMed ID: 30059640
[TBL] [Abstract][Full Text] [Related]
10. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness.
Kakouros N; Kickler TS; Laws KM; Rade JJ
J Thromb Haemost; 2013 Oct; 11(10):1814-22. PubMed ID: 24118870
[TBL] [Abstract][Full Text] [Related]
11. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention.
Gaglia MA; Torguson R; Pakala R; Xue Z; Sardi G; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
J Interv Cardiol; 2011 Dec; 24(6):529-34. PubMed ID: 21919956
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
[TBL] [Abstract][Full Text] [Related]
13. Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Luo Y; Li J; Liu X; Xu J; Ye Z; Yao Y; Liu X; Lai Y
Thromb Res; 2016 Mar; 139():114-20. PubMed ID: 26916306
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
[TBL] [Abstract][Full Text] [Related]
15. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
16. Monitoring ASA and P2Y12-specific platelet inhibition--comparison of conventional (single) and multiple electrode aggregometry.
Krüger JC; Meves SH; Kara K; Mügge A; Neubauer H
Scand J Clin Lab Invest; 2014 Oct; 74(7):568-74. PubMed ID: 25296945
[TBL] [Abstract][Full Text] [Related]
17. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Price MJ; Angiolillo DJ; Teirstein PS; Lillie E; Manoukian SV; Berger PB; Tanguay JF; Cannon CP; Topol EJ
Circulation; 2011 Sep; 124(10):1132-7. PubMed ID: 21875913
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
19. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting.
Toma C; Zahr F; Moguilanski D; Grate S; Semaan RW; Lemieux N; Lee JS; Cortese-Hassett A; Mulukutla S; Rao SV; Marroquin OC
Am J Cardiol; 2012 Apr; 109(8):1148-53. PubMed ID: 22277895
[TBL] [Abstract][Full Text] [Related]
20. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
